SOURCE: Vicor Technologies, Inc.

Vicor Technologies, Inc.

February 02, 2011 08:30 ET

Vicor Technologies Names Dr. Steve Watts Director of Sports Medicine

BOCA RATON, FL--(Marketwire - February 2, 2011) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Steve A. Watts, MD, was named Director of Sports Medicine, a new part-time position. Vicor Technologies (http://www.vicortech.com) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

"We are very fortunate to have Dr. Watts joining us as Director of Sports Medicine. As Associate Professor in the Department of Family Medicine at the University of Mississippi Medical Center -- UMMC is a frequent partner on many of our PD2i Analyzer™ studies -- Dr. Watts instituted the Family Medicine Sports Medicine curriculum and clinical experience at UMMC. He has lectured and written extensively on the treatment and management of a wide variety of sports-related conditions -- including head injury and sudden death, which are two established targets for the PD2i Analyzer™. We are extremely gratified to have him working with our scientists and clinical trial partners to validate the ability of our PD2i Analyzer™ to serve as a diagnostic for a range of sports-related disorders," stated Mr. Fater.

As Vicor's Director of Sports Medicine, Dr. Watts will oversee clinical trials to test the efficacy of Vicor's PD2i Analyzer™ to diagnose concussion and other sports-related conditions. Vicor is currently involved in a study to assess concussions in competitive athletes in collaboration with UMMC and Belhaven University. Additional sports condition-related PD2i Analyzer™ clinical trials are currently being explored with additional universities.

Dr. Watts is a tenured Associate Professor in the UMMC Department of Orthopedic Surgery and Rehabilitation and the Department of Family Medicine, where he instituted the Family Medicine Sports Medicine Curriculum and Clinical Experience for resident physicians in the UMMC Family Medicine Residency Training Program. He also serves as Director for the Sports Medicine Fellowship Program, as well as University Sports Medicine staff physician at UMMC, team physician for the Mississippi Braves, Belhaven University Blazers, Provine High School Rams, Lanier High School Bulldogs, and Canton High School Tigers, and a member of the National Rodeo Sports Medicine staff. He was recently awarded an honorary academic appointment as Visiting Professor in the Division of Surgical & Interventional Science at the University College London.

Dr. Watts is a member of the Society of Teachers of Family Medicine, for which he serves on the Sports Medicine Committee; American Medical Society for Sports Medicine, for which he served on the Education Committee; American College of Sports Medicine; the USA Amateur Boxing Association; American Orthopedic Society for Sports Medicine; American Medical Association; Mississippi State Medical Association, the American Academy of Family Physicians; Texas Academy of Family Physicians; and Mississippi Academy of Family Physicians.

Dr. Watts serves on the board of directors of the Mississippi High School Sports Medicine Advisory Committee; Mississippi Academy of Family Physicians, and Mississippi Academy of Family Physicians Foundation. He is a former director of the John Peter Smith Hospital Residency Alumni Foundation; Texas Healthcare Network; Texas Academy of Family Physicians Foundation, and Texas Academy of Family Physicians.

Dr. Watts is board certified by the American Board of Family Practice and is a Fellow of the American Academy of Family Physicians. He holds a Certification of Additional Qualification in Sports Medicine. Dr. Watts earned his MD at the University of Texas Southwestern Medical School. He holds a Texas Secondary Teacher's Certification in Biology and Chemistry from the University of Houston and a BS in Biology and Chemistry, cum laude, from the University of Houston.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions, such as the University of Mississippi Medical Center; Bellhaven University; Mississippi Braves; Belhaven University Blazers; Provine High School Rams; Lanier High School Bulldogs; Canton High School Tigers; National Rodeo Sports Medicine; University College London; ACGME; University of Mississippi High School Sports Medicine; Your Health First; Texas Health Care Network; Healthfirst Medical Associates; Arlington Family Medicine Clinic; Society of Teachers of Family Medicine; American Medical Society for Sports Medicine; American College of Sports Medicine; USA Amateur Boxing Association; American Orthopedic Society for Sports Medicine; American Medical Association; Mississippi State Medical Association; American Academy of Family Physicians; Texas Academy of Family Physicians; Mississippi Academy of Family Physicians; Mississippi High School Sports Medicine Advisory Committee; Mississippi Academy of Family Physicians; Mississippi Academy of Family Physicians Foundation; John Peter Smith Hospital Residency Alumni Foundation; Texas Healthcare Network; Texas Academy of Family Physicians Foundation; Texas Academy of Family Physicians; American Board of Family Practice; American Academy of Family Physicians; American Academy of Family Physicians; American Board of Family Practice; University of Texas Southwestern Medical School; University of Houston; and the U.S. Army Institute for Surgical Research, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People's Republic of China; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 11-06

Contact Information